Pulmonary Rehab Can Be Tough to Find for People With COPD

Follow Drugslib on

Medically reviewed by Drugs.com.

By Ernie Mundell HealthDay Reporter

WEDNESDAY, Feb. 7, 2024 -- Pulmonary rehabilitation can be a lifeline for millions of Americans coping with COPD or other chronic lung ailments.

However, new research finds that travel time and cost issues put pulmonary rehab programs out of reach for many patients.

“Access to programs within a reasonable amount of travel time is key,” stressed study lead author Dr. Peter Kahn, a pulmonary and critical care fellow at the Yale School of Medicine.

“First, many patients with chronic respiratory conditions require oxygen supplementation," he explained in a Yale news release. "Long commutes may mean they have to transport multiple oxygen tanks or battery supplies, which may cause patients to forgo the treatment. Second, because exertional [exercise] intolerance is a symptom of these diseases, long travel can be incredibly taxing and also serve as a barrier to participation.”

The findings were published Feb. 5 in the journal JAMA Network Open.

As the researchers explained, pulmonary rehab programs are often utilized by people with chronic obstructive pulmonary disease (COPD), interstitial lung disease or pulmonary hypertension.

These programs have patients meet with skilled health care workers to foster techniques that will make day-to-day life with a respiratory disorder easier. For example, they'll learn strategies to better harness their daily energy or maximize supplemental oxygen therapy.

All of this "has been demonstrated across almost the entirety of pulmonary medicine to improve patient health and patient-reported outcomes,” Kahn said. "Through these programs, patients not only gain a more comprehensive understanding of their condition, but also improve their exercise tolerance in a meaningful way.”

But just how accessible are such programs for patients across the United States?

In the study, Kahn's group "used massive geographic data sets and computational infrastructure to compute hundreds of millions of travel times" to and from rehab programs.

The team found that 80% of Americans do live within a half-hour's drive of a facility offering pulmonary rehab.

But that still leaves 14 million people -- mostly concentrated in the West and Midwest -- who must drive more than an hour to reach a rehab program.

Kahn's team believes telehealth might be able to help some of these patients, although long-term studies are needed to confirm that.

Cost can be an impediment to access, too.

“Insurance payers, both government and private, do not sufficiently reimburse pulmonary rehabilitation programs for the people, equipment and supplies needed to effectively run them,” Kahn said.

Too often, insurance companies also limit the number of rehab sessions they'll cover for patients, he added.

“If you’re someone with a chronic respiratory condition like advanced COPD, you really need ongoing therapeutic sessions,” Kahn said. “But right now, payers limit patients to a small number of lifetime sessions relative to the long-term burden of the disease. And that needs to change.”

Sources

  • Yale University, news release, Feb. 5, 202

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-02-07 22:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords